IL1B and ulcerative colitis: In conclusion, our results revealed that oral administration of BCP in DSS-induced ulcerative colitis mice improved colitis by reducing MPO activity, IL-1β, IL-6, and TNF-α concentrations, as well as the abundance of bacteria that cause intestinal immune imbalance.